JPH0684952B2 - Analytical method and sensor electrode - Google Patents
Analytical method and sensor electrodeInfo
- Publication number
- JPH0684952B2 JPH0684952B2 JP60226016A JP22601685A JPH0684952B2 JP H0684952 B2 JPH0684952 B2 JP H0684952B2 JP 60226016 A JP60226016 A JP 60226016A JP 22601685 A JP22601685 A JP 22601685A JP H0684952 B2 JPH0684952 B2 JP H0684952B2
- Authority
- JP
- Japan
- Prior art keywords
- paracetamol
- enzyme
- electrode
- sensor electrode
- aromatic primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004458 analytical method Methods 0.000 title claims description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 52
- 229960005489 paracetamol Drugs 0.000 claims description 46
- 102000004190 Enzymes Human genes 0.000 claims description 31
- 108090000790 Enzymes Proteins 0.000 claims description 31
- 108010000519 Aryl-acylamidase Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- -1 N-acylated aromatic primary amines Chemical class 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 3
- 241000251468 Actinopterygii Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 238000011088 calibration curve Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 238000002484 cyclic voltammetry Methods 0.000 description 6
- 238000003359 percent control normalization Methods 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 239000010439 graphite Substances 0.000 description 5
- 229910002804 graphite Inorganic materials 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920003319 Araldite® Polymers 0.000 description 3
- 108010093096 Immobilized Enzymes Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910021397 glassy carbon Inorganic materials 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 231100000149 liver necrosis Toxicity 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241001149959 Fusarium sp. Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 101710180958 Putative aminoacrylate hydrolase RutD Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical class Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 238000006056 electrooxidation reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001075 voltammogram Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/817—Enzyme or microbe electrode
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】 本発明は化学センサ、特に全血中のN−アセチル芳香族
第一アミン、例えばパラセタモールの存在を検出し、そ
の量を測定するかまたはその水準を監視することができ
る化学センサに関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention is capable of detecting the presence of chemical sensors, particularly N-acetylaromatic primary amines, such as paracetamol, in whole blood and measuring its amount or monitoring its level. It relates to a chemical sensor.
パラセタモール(N−アセチルp−アミノフェノール)
は迅速に作用し一般に副作用を有しない鎮痛薬として広
範囲に使用されている。この医薬は有効な作用および他
の医薬との好ましい相互作用を有するが、これを入手す
ることができることにより、この医薬を自殺に使用する
ことが多くなってきた。Paracetamol (N-acetyl p-aminophenol)
It is widely used as an analgesic that acts quickly and generally has no side effects. Although this drug has efficacious effects and favorable interactions with other drugs, the availability of it has led to its increased use in suicide.
致死薬量は広汎な肝壊死の結果として死に至らしめる。Lethal doses are lethal as a result of extensive liver necrosis.
パラセタモールは、苦痛受体に敏感であると考えられる
プロスタグランジンおよびリポ多糖類の或る種のものの
合成を阻止することにより作用するものと考えられる。Paracetamol is thought to act by blocking the synthesis of certain of the prostaglandins and lipopolysaccharides that are thought to be sensitive to pain receptors.
人体からこの物質の排泄は肝臓における抱合後起るもの
と考えられる。現在の理論は、パラセタモールは低濃度
で硫酸塩またはグルクロニドと抱合するが、高濃度では
システインを形成する酸化代謝路がつくられ、メルカプ
ツール酸が抱合し次いで活性中間体と減少したグルタチ
オンとの反応が行われる。パラセタモールの極めて高い
濃度で、肝の減少したグルタチオン貯留が枯渇するよう
になり結果として起る高水準の活性化した中間体が肝細
胞壊死を起すと考えられる。更に細胞の損傷を起す中間
体の活性の化学基はサルフヒドリル基であると考えられ
る。Excretion of this substance from the human body is considered to occur after conjugation in the liver. The current theory is that paracetamol conjugates at low concentrations with sulfate or glucuronide, but at higher concentrations oxidative metabolic pathways are formed to form cysteine, mercapturic acid conjugates and then with active intermediates and reduced glutathione. The reaction is carried out. It is believed that extremely high concentrations of paracetamol become depleted in hepatic diminished glutathione pools and the resulting high levels of activated intermediates cause hepatocyte necrosis. Furthermore, the active chemical group of the intermediate that causes cell damage is thought to be the sulfhydryl group.
肝壊死の臨床上の初期は、パラセタモール中毒の明らか
な症状だけであり、摂取後数時間10〜12時間までは起ら
ない。更に、この中毒は、壊死が起る前、従って最初の
臨床上の徴候がおこる前に処置しなければならない。通
常治療は、胃洗または活性炭の如き吸着剤の摂取(摂取
後短時間に医学的手当が利用できる場合)、次いで活性
化した中間体の作用を競争して阻止するサルフヒドリル
基を有する物質の投与を含む。The early clinical phase of liver necrosis is the only obvious symptom of paracetamol intoxication, which does not occur until a few hours 10 to 12 hours after ingestion. Furthermore, this poisoning must be treated before necrosis occurs and thus the first clinical signs. The usual treatment is gastric lavage or ingestion of adsorbents such as activated charcoal (if medical benefits are available shortly after ingestion), followed by administration of substances with sulfhydryl groups that competitively block the action of activated intermediates. including.
然し、サルフヒドリルを有する解毒薬の投与は、摂取後
10時間以上後または血清のパラセタモール濃度に正しく
合わない場合には危険であることを確かめた。However, administration of sulfhydryl-containing antidotes is
After 10 hours or more, it was confirmed to be dangerous if the serum paracetamol concentration was not met correctly.
従ってパラセタモールの量の迅速であり且つ正確な測定
が行なえ、これにより診断および有効な治療を早期に確
立し得る方法を提供することが望ましい。Therefore, it would be desirable to provide a method by which a rapid and accurate determination of paracetamol levels can be made, thereby enabling early establishment of a diagnostic and effective treatment.
かかる方法を提供せんとする従来の試みは、時間、熟練
および高価な装置を必要とするクロマトグラフ法に基づ
くものであった。或いはまた、p−アミノフェノール
(PAP)の検出に基づく更に特定の比色法が用いられて
きた。p−アミノフェノール(MP186℃)はパラセタモ
ールの酵素減成により生成され、この場合も高価な装置
および熟練者が必要である。比色法の特別な制限は赤血
球の干渉により全血よりはむしろ血清または血漿を使用
することにある。Previous attempts to provide such methods have been based on chromatographic methods that require time, skill and expensive equipment. Alternatively, a more specific colorimetric method based on the detection of p-aminophenol (PAP) has been used. p-Aminophenol (MP186 ° C) is produced by enzymatic degradation of paracetamol, again requiring expensive equipment and skilled personnel. A particular limitation of the colorimetric method is the use of serum or plasma rather than whole blood due to red blood cell interference.
従って大きく且つ費用のかかる装置を用いることなく比
較的未熟な人により行われるパラセタモールの分析方法
を提供することが望ましい。かかる方法は全血を用い試
験管内でまたは生体内で使用されるのが好ましい。Therefore, it would be desirable to provide a method for the analysis of paracetamol which is performed by a relatively immature person without the use of large and expensive equipment. Such methods are preferably used in vitro with whole blood or in vivo.
欧州特許出願第82305597号には、導電性物質からなり、
少くともその外面に酵素と、酵素が接触反応に有効であ
る場合電子を電極に輸送するメディエイタ化合物の組合
せを有するセンサ電極が開示され、請求されている。European Patent Application No. 82305597 consists of a conductive material,
Disclosed and claimed is a sensor electrode having a combination of an enzyme on at least its outer surface and a mediator compound that transports electrons to the electrode when the enzyme is effective for the catalytic reaction.
かかる電極の目的は上記酵素により触媒作用が及ぼされ
る反応を行う能力のある1種又はそれ以上の選ばれた成
分の存在の検知、その量の測定及び/又は監視である。The purpose of such electrodes is to detect the presence, measure and / or monitor the presence of one or more selected components capable of carrying out a reaction catalyzed by the enzyme.
本発明は、特定の一般的反応機構がパラセタモール及び
関連化合物の分析の基礎として特に有用であることを知
見したことに基づく。The present invention is based on the finding that certain general reaction mechanisms are particularly useful as the basis for the analysis of paracetamol and related compounds.
本発明の第1の観点において、適当な電位に保った電極
を次のサンプル及び酵素を含む系と接触させる型の検定
方法を提供する: a)パラセタモール又はその誘導体が含まれると思われる
サンプル、及び、 b)N−アシル化された芳香族第一アミン又はその誘導体
の加水分解に触媒作用を及ぼす能力のある酵素、 であり、但し電極中を流れる電流は形成される加水分解
生成物の量、従ってサンプル中のN−アシル化された芳
香族第一アミン又はその誘導体の濃度の尺度である。In a first aspect of the invention there is provided an assay method of the type in which an electrode kept at a suitable potential is contacted with the following sample and a system containing the enzyme: a) a sample suspected of containing paracetamol or a derivative thereof, And b) an enzyme capable of catalyzing the hydrolysis of an N-acylated aromatic primary amine or derivative thereof, provided that the current flowing through the electrode is the amount of hydrolysis product formed. , Thus a measure of the concentration of N-acylated aromatic primary amine or derivative thereof in the sample.
この系はメディエイタを使用せず、この点で本出願人の
先願とは異なることを留意すべきである。It should be noted that this system does not use a mediator and in this respect differs from the applicant's earlier application.
発明の名称が“分析装置及びそのためのセンサ電極”で
ある本出願人の係属する出願にセンサ電極の性質及び製
造が開示されている。かかる電極は、本発明の実施に好
ましく、電極はその表面に酵素が被着されるが、メディ
エイタ化合物が用いられないのが好ましい。The nature and manufacture of the sensor electrode is disclosed in the applicant's pending application, whose title is "analyzer and sensor electrode therefor". Such electrodes are preferred for the practice of the present invention, the electrodes being coated with an enzyme on their surface, but preferably without a mediator compound.
従って、本発明の第2の観点は、表面にパラセタモール
又はパラセタモールの誘導体を生成物に加水分解するの
に触媒作用を及ぼす能力のある酵素を有するセンサ電極
で、但し電極の中を流れる電流が行なわれる反応及びそ
れによる上記表面でのパラセタモール又はその誘導体の
濃度の尺度である。Therefore, a second aspect of the invention is a sensor electrode having an enzyme on the surface which is capable of catalyzing the hydrolysis of paracetamol or a derivative of paracetamol to the product, provided that the current flowing through the electrode is And the resulting concentration of paracetamol or its derivative at the surface.
便利なことには、酵素はEC3.5.1.13として規定されてい
る型のものでありアリールアシルアミダーゼ〔IUB(国
際生化学連合)〕(他にアリールアシルアミドアミノヒ
ドロラーゼとして知られている)として命名されてい
る。Conveniently, the enzyme is of the type defined as EC 3.5.1.13 and is as an aryl acylamidase [IUB] (otherwise known as aryl acylamido aminohydrolase). It is named.
酵素は細菌から得るのが好ましい。The enzyme is preferably obtained from bacteria.
電極表面における分析のために、パラセタモールをp−
アミノフェノールに直接転化させる多数の細菌の酵素が
研究されている。Paracetamol was added to the p- for analysis on the electrode surface.
A large number of bacterial enzymes that convert directly to aminophenols have been studied.
これらのアリールアシルアミダーゼを使用する分析系で
起るプロセスに対して次の反応式が仮定されている: 細菌のアリールアシルアミダーゼの作用下に、パラセタ
モールは加水分解してp−アミノフェノールおよび酢酸
を生成する。溶液中のp−アミノフェノールと電極表面
との間の電位差が、電極における低エネルギー帯が電子
によって見い出されるような大きさである場合には、電
子は電極の伝導帯によって受け取られる。従って、電極
に電位差が加えられた際に、電気酸化(electro-oxidat
ion)が基準電極に関して起る。The following reaction schemes have been postulated for the processes that occur in analytical systems using these aryl acylamidases: Under the action of bacterial aryl acylamidases, paracetamol hydrolyzes to produce p-aminophenol and acetic acid. If the potential difference between p-aminophenol in solution and the electrode surface is such that the low energy band at the electrode is found by the electron, then the electron will be accepted by the conduction band of the electrode. Therefore, when a potential difference is applied to the electrodes, electro-oxidation
ion) occurs with respect to the reference electrode.
本発明の特定例では、酸素をフザリウム(Fusarium)種
から生成させる。In a particular example of the invention, oxygen is generated from Fusarium species.
本発明の他の特定例では、酸素をプソイドモナス(Pseu
domonas)種から生成させる。In another particular embodiment of the invention, oxygen is added to Pseudomonas (Pseu).
domonas) seeds.
次に本発明を図面を参照して例について説明する。The invention will now be described by way of example with reference to the drawings.
種々の材料の作用電極を使用した: 電極ディスクとテフロン被覆内に収容されている黄銅連
結棒とから金、白金、ガラス状炭素およびニッケル(中
実のもの)電極を作った。実験室において黒鉛ペースト
電極をアラルダイト(araldite)(レディオ・スペアズ
(Radio Spares)社から入手)内に収容されている青銅
連結部材から作った。アラルダイト被覆(ガラスカラー
内に保持されている)はコネクターを露出させるために
一端に孔を設けたコップを具えていた。黒鉛ペースト材
料をこのコップ内に充填した。Working electrodes of various materials were used: Gold, platinum, glassy carbon and nickel (solid) electrodes were made from electrode disks and brass tie rods housed in Teflon coatings. In the laboratory, graphite paste electrodes were made from bronze interconnects housed in araldite (obtained from Radio Spares). The Araldite coating (held in the glass collar) included a cup with a hole at one end to expose the connector. Graphite paste material was filled into this cup.
ヌジョール(Nujol)と混合した黒鉛粉末またはアラル
ダイトと混合した黒鉛粉末を使用して黒鉛ペーストを作
り、これをコップ内で硬化させた。いずれの場合にも対
向電極を作用電極材料の近くに保持して電子が容易に流
れるようにした。A graphite paste was made using graphite powder mixed with Nujol or graphite powder mixed with Araldite and cured in a cup. In either case, the counter electrode was held near the working electrode material so that electrons could easily flow.
次の例は本発明を含む技術を使用した結果を示す。The following example shows the results using a technique involving the present invention.
参考例1 P−アミノフェノールのサイクリックボルタンメトリー リン酸二水素カリウム〔5.31g;ブリティッシュドラッグ
ハウジズ(BDH社製のアナラー(Analar)〕及びリン酸
水素二カリウム〔13.92g;BDH社製のアナラー)より緩衝
液を調整し、この際これらをミリーQ水(Milli-Q wate
r)に溶解して、pHを7に調節し最終体積を1リットル
とした。Reference Example 1 Cyclic voltammetry of P-aminophenol Potassium dihydrogen phosphate [5.31 g; British Drug Houses (Analar manufactured by BDH) and dipotassium hydrogen phosphate [13.92 g; Analer manufactured by BDH] More buffer solution was prepared. At this time, these were added to Milli-Q wate.
Dissolved in r), the pH was adjusted to 7 and the final volume was 1 liter.
p−アミノフェノール溶液を、約80mlのミリーQ水に5
4.56mgのp−アミノフェノール(BDH)を溶解すること
により調整し、0.1MNaOHでpH11に調節した。次いで溶液
を0.1MHClでpH9まで酸性化し、ミリーQ水で最終体積を
100mlとした。p−アミノフェノール溶液を光から保護
し調整後直ちに使用した。Add p-aminophenol solution to approximately 80 ml of Milly Q water.
Adjusted by dissolving 4.56 mg of p-aminophenol (BDH) and adjusted to pH 11 with 0.1 M NaOH. The solution was then acidified to pH 9 with 0.1M HCl and the final volume was adjusted with Milly Q water.
It was 100 ml. The p-aminophenol solution was protected from light and used immediately after preparation.
作用電極は異なる材料、例えば金、ガラス状カーボン及
び特に熱分解グラファイトの範囲から作られた。電極は
電極表面から酸化生成物及び不純物を除去するために水
に0.3μのアルミナ(BDH)のスラリーを使用して実験の
間定期的に浄化した。次いでアルミナを電極表面から超
音波により除去した。The working electrode was made from a range of different materials such as gold, vitreous carbon and especially pyrolytic graphite. The electrode was periodically cleaned during the experiment using a slurry of 0.3 μ alumina (BDH) in water to remove oxidation products and impurities from the electrode surface. The alumina was then ultrasonically removed from the electrode surface.
サイクリックボルタモグラムを、飽和カロメル電極(SC
E)に対して電位をゼロ〜+400mV及び−200mVの間を掃
引することにより溶液の範囲から得た。印加電位は50mV
/sの操作速度を使用するポテンシォスタット(ジェイト
ロン社・エー・エス・サイエンティフック・アビングト
ン)により制御した。The cyclic voltammogram is displayed on a saturated calomel electrode (SC
For E) the potential was obtained from a range of solutions by sweeping between zero and +400 mV and -200 mV. Applied potential is 50 mV
It was controlled by a potentiostat (Jtron, AS Scientific Hook Abington) using an operating speed of / s.
生じた酸化電流をグルドシリース60000チャートレコー
ダーで記録した。X軸は印加電位を、Y軸は生じた電流
を示した。p−アミノフェノールのサイクリックボルタ
モグラム(最終濃度1mMで)を第2図に示す。The oxidation current generated was recorded with a Gludocilese 60000 chart recorder. The X-axis shows the applied potential and the Y-axis shows the generated current. A cyclic voltammogram of p-aminophenol (at a final concentration of 1 mM) is shown in FIG.
実施例1 アリールアシルアミダーゼを組み入れたセンサ パラセタモール(N−アセチルp−アミノフェノール;
シグマケミカル社製)をリン酸カリウム緩衝液に溶解し
て25mMの最終濃度を与えた。プソイドモナス種から抽出
したアリールアシルアミダーゼを、アプライドマイクロ
バイオロジーエンドリサーチ、ポートンダウン、サリス
バリーに対するP.H.L.S.センターにより10mlガラスビン
に凍結乾燥して供給した。酵素を−20℃で保存し、フザ
リウム種から抽出されたアリールアシルアミダーゼがシ
グマケミカル社により供給されたのでガラスびん当り1m
lのミリーQ水で再生した。Example 1 Sensor incorporating aryl acylamidase Paracetamol (N-acetyl p-aminophenol;
Sigma Chemical Co.) was dissolved in potassium phosphate buffer to give a final concentration of 25 mM. Aryl acylamidases extracted from Pseudomonas species were lyophilized and supplied in 10 ml glass bottles by PHLS Center for Applied Microbiology End Research, Porton Down, Salisbury. The enzyme was stored at -20 ° C and the aryl acylamidase extracted from Fusarium sp. Was supplied by Sigma Chemical Co.
Reproduced with l Millie Q water.
酵素溶液を、アトキンソン・エー・ハモンド、ピー・エ
ム・ブライス・シー・ピーおよびスカウェン・エム・デ
ィーの方法(英国特許第2089978B号)を用いて定期的に
分析した。この系では、0.0880アンモニア0.4mlと混合
した無水硫酸銅の0.2%(W/V)水溶液25mlを含む0.1%
(W/V)オルトクレゾール水溶液1mlとアンモニア性硫酸
銅0.1mlを、使い捨てキュベット内の水1.4ml中に添加し
た。この溶液を十分に混合し、更に標準p−アミノフェ
ノール溶液0.5mlを添加した。次いでこの溶液を再度混
合し、5分間静置した後615nmにおいて溶液の吸収を測
定した。酵素の1ユニットを、pH7および温度37℃にお
ける1分当りのパラ・アミノフェノールへのパラセタモ
ール1μmolの転化として規定した。The enzyme solution was analyzed periodically using the method of Atkinson A. Hammond, P.M.Blythe C.P. and Skawen M.D. (British Patent No. 2089978B). In this system, 0.1% containing 25 ml of 0.2% (W / V) aqueous solution of anhydrous copper sulfate mixed with 0.4 ml of 0.0880 ammonia.
(W / V) Orthocresol aqueous solution 1 ml and ammoniacal copper sulfate 0.1 ml were added to water 1.4 ml in a disposable cuvette. This solution was mixed well and 0.5 ml of standard p-aminophenol solution was added. The solution was then remixed and allowed to sit for 5 minutes before measuring the absorption of the solution at 615 nm. One unit of enzyme was defined as the conversion of 1 μmol paracetamol to para-aminophenol per minute at pH 7 and temperature 37 ° C.
使用した電極は上述の参考例で述べたものと同じもので
ある。The electrodes used are the same as those described in the above reference example.
サイクリックボルタモグラムでは、セルにパラセタモー
ル溶液24μl(上述の如き25mM)と緩衝溶液576μlと
を入れた。For cyclic voltammograms, cells were loaded with 24 μl of paracetamol solution (25 mM as above) and 576 μl of buffer solution.
サイクリックボルタモグラムを0.9Uアリールアシルアミ
ダーゼ(上記酵素溶液120μl)の存在下および不存在
下の双方で記録した。反応の開始を確実ならしめるため
に、走査開始前に各サンプルを37℃で2分間温置した。Cyclic voltammograms were recorded both in the presence and absence of 0.9 U arylacyl amidase (120 μl of the enzyme solution above). To ensure that the reaction started, each sample was incubated at 37 ° C for 2 minutes before starting the scan.
サイクリックボルタモグラムを第3図に示す。第3図で
は、走査開始前のアリールアシルアミダーゼ溶液の添加
の際、ボルタモグラムの輪郭に実質的変化が観察された
ことを示している。これは、酵素によるパラ−アミノフ
ェノールへのパラセタモールの触媒転化に起因する。The cyclic voltammogram is shown in FIG. FIG. 3 shows that substantial changes were observed in the voltammogram contour upon addition of the aryl acylamidase solution prior to the start of the scan. This is due to the catalytic conversion of paracetamol to para-aminophenol by the enzyme.
実施例2 緩衝溶液での定常状態測定 定常状態測定では、かきまぜた溶液に固定電位を印加し
た際に生ずる電流を、時間ベースとしてX軸を用いチャ
ートレコーダのY軸で評価した。系が平衡になるまでの
2分間が経過した後に、電位が37℃でSCEに対し+250mV
で安定した。溶液のかきまぜは、酸化に有効である電極
に隣接する物質層の再補充を確実に行なわしめ、これに
より、電極で生じた電流は試薬の消耗により減衰するこ
とがなくなる。Example 2 Steady-State Measurement in Buffer Solution In steady-state measurement, the current produced when a fixed potential was applied to the agitated solution was evaluated on the Y axis of a chart recorder using the X axis as the time base. After 2 minutes have passed until the system reaches equilibrium, the potential is +250 mV against SCE at 37 ° C.
Stable in. Agitation of the solution ensures that the layer of material adjacent to the electrode that is effective for oxidation is replenished, so that the current generated at the electrode is not attenuated by exhaustion of the reagent.
かきまぜを行なった溶液はアリールアクリルアミダーゼ
溶液200μl(1.5ユニット)と緩衝溶液800μl(pH7)
とを含む。定常状態の電気化学的測定をパラセタモール
溶液の増加する量の下で行ない、パラセタモールに関す
る一次検量線を作成した。これを第4図に示す。The stirred solution is 200 μl (1.5 units) of aryl acrylic amidase solution and 800 μl (pH 7) of buffer solution.
Including and Steady-state electrochemical measurements were performed under increasing amounts of paracetamol solution to generate a primary calibration curve for paracetamol. This is shown in FIG.
同様の一次検量線をpH7.5の緩衝溶液(リン酸二水素カ
リウム2.18g(BDH社製アナラーと、ミリーQ水に溶解し
たリン酸水素二カリウム19.17g(BDH社製アナラー)と
から作り、pH7.5に調整し、最終容積を1とした)に
て作成した。これを第5図に示す。A similar primary calibration curve was prepared from a pH 7.5 buffer solution (potassium dihydrogen phosphate 2.18 g (BDH Analer) and dipotassium hydrogen phosphate 19.17 g (BDH Analer) dissolved in Milly Q water, The pH was adjusted to 7.5 and the final volume was set to 1.) This is shown in FIG.
温置混合物のpHを更に8.0まで高めると(ミリーQ水に
溶解したトリズマ塩基(Trizmabase)12.11g(シグマケ
ミカル社製)より調整した緩衝液を1MのHClでpH8に調整
し、最終容積を1とした)、パラセタモールに対し極
めて不十分な応答が見られ、また0.5mM以上のパラセタ
モール濃度において直線から逸脱した第6図に示す検量
線が生じた。When the pH of the incubation mixture was further raised to 8.0 (12.11 g of Trizmabase dissolved in Milly-Q water (manufactured by Sigma Chemical Co.), the pH was adjusted to 8 with 1M HCl, and the final volume was adjusted to 1 , An extremely inadequate response to paracetamol was observed, and a calibration curve shown in FIG. 6 that deviated from the straight line was generated at a paracetamol concentration of 0.5 mM or more.
pH7.0と7.5の間の緩衝液を用いて得たパラセタモールに
関する検量線が未知サンプルの直読値に関連させて使用
し、パラセタモール濃度を決定することができた。A calibration curve for paracetamol obtained with buffers between pH 7.0 and 7.5 could be used in conjunction with the direct readings of unknown samples to determine paracetamol concentration.
実施例3 100%対照血清での定常状態の測定 対照血清(モニトロール(Monitrol)IIE:スイス国メル
ツ・アンド・デードAG)をバイアル当り3.5mlのミリー
Q水に懸濁させ(製造者の報告書に記載されている容積
の70%)、次いで製造者の報告書に従い混合して143%
(最終濃度)の対照血清を得た。この対照血清にパラセ
タモール(シグマケミカル社製)を添加して最終濃度4.
29mMを得た。143%の対照血清で上記溶液を希釈する
と、血清中0〜4.29mMのパラセタモール濃度範囲が得ら
れた。Example 3 Steady state determination with 100% control serum Control serum (Monitrol IIE: Merz & Dade AG, Switzerland) was suspended in 3.5 ml Milly-Q water per vial (manufacturer's report). 70% of the volume listed in), then 143% mixed according to the manufacturer's report.
Control serum (final concentration) was obtained. Paracetamol (manufactured by Sigma Chemical Co.) was added to this control serum to give a final concentration of 4.
29 mM was obtained. Dilution of the above solution with 143% control serum gave a range of paracetamol concentrations in serum from 0 to 4.29 mM.
かきまぜを行なったセルには、143%対照血清中パラセ
タモール溶液700μlと、1Mのリン酸カリウム緩衝溶液
(pH7.0)100μlと、アリールアシルアミダーゼ溶液
(1.5ユニット)200μlとが入っていた(かきまぜを行
なったセル内の血清の最終濃度は100%相当であっ
た)。定常状態電流を上記実施例2で述べた如く2度測
定した。100%対照血清におけるパラセタモールに関す
る検量線を第7図に示す。The agitated cell contained 700 μl of paracetamol solution in 143% control serum, 100 μl of 1M potassium phosphate buffer solution (pH 7.0), and 200 μl of aryl acylamidase solution (1.5 units) (agitated. The final concentration of serum in the cells performed was 100% equivalent). The steady state current was measured twice as described in Example 2 above. The calibration curve for paracetamol in 100% control serum is shown in FIG.
比較研究において、143%の対照血清におけるパラセタ
モール溶液を、標準パラセタモール分析方法〔ケンブリ
ッジ ライフ サイエンス(CLS)〕を用いて分析し
た。第3図に示すCLS方法により決定したパラセタモー
ル濃度と、測定した定常状態電流との間に良好なる相関
関係を見い出した。In a comparative study, paracetamol solutions at 143% control serum were analyzed using the standard paracetamol assay method [Cambridge Life Sciences (CLS)]. A good correlation was found between the measured steady-state current and the paracetamol concentration determined by the CLS method shown in FIG.
フサリウム酵素以上のプソイドモナス酵素の特別なる利
点は、後者が周囲温度および中性pH(全血清のpHは約7.
2である)で良好に作動することである。かかる最適条
件により、特別なる実験室条件を必要とせず如何なる環
境(例えば手術室)においても使用することのできるバ
イオセンサの製造が容易となった。The particular advantage of Pseudomonas enzymes over Fusarium enzyme is that the latter is at ambient temperature and neutral pH (pH of whole serum is around 7.
2) works well. Such optimal conditions have facilitated the production of biosensors that can be used in any environment (eg operating room) without the need for special laboratory conditions.
実施例4 膜への酵素固定化 固定したすべての酵素を、酢酸セルロースをアセトンに
溶解した溶液と種々の濃度で混合した。次いでこの溶液
を電極表面に配置し、アセトンを蒸発させ(乾燥空気流
を作用させるかまたは作用させることなしに行なう)、
取り込まれた酵素を有する酢酸セルロース膜を残留させ
た。次いで、この酵素電極を用いてパラセタモールの固
定濃度を検出した(第9図参照)。Example 4 Enzyme Immobilization on Membrane All immobilized enzymes were mixed at various concentrations with a solution of cellulose acetate in acetone. The solution is then placed on the electrode surface and the acetone is evaporated (with or without a dry air stream),
The cellulose acetate membrane with the entrapped enzyme was left behind. Next, the fixed concentration of paracetamol was detected using this enzyme electrode (see FIG. 9).
酵素は、この方法において固定化した場合に、その活性
度を明らかに保持した。酵素の閉じ込は、これが固定化
膜と共有結合を形成しないのでその構造に重大な拘束を
与えず、この事が多くのその自然活性を保持させた。The enzyme clearly retained its activity when immobilized in this way. Encapsulation of the enzyme did not significantly constrain its structure as it does not form a covalent bond with the immobilized membrane, which retained many of its natural activities.
固定化酵素に遭遇する遅い応答時間は、酵素活性(閉じ
込めにより課せられる運動における小さい拘束によっ
て)および膜を通る生成物輸送における制限によるもの
と思われる。The slow response times encountered with immobilized enzymes are likely due to enzyme activity (due to a small constraint on movement imposed by confinement) and restriction in product transport across the membrane.
酵素を固定化することのできる特殊な利点は次のよう
に: a)パラセタモールを感知する一成分装置を製造できるこ
と、 b)酵素を再使用できること、および c)酵素特性を固定化法によりセンサの応答時間を短縮す
るように変えることができることである。The particular advantages of being able to immobilize an enzyme are: a) the ability to make a one-component device that senses paracetamol, b) the ability to reuse the enzyme, and c) the enzymatic properties of the sensor by immobilization. It can be changed to shorten the response time.
本発明の範囲内で種々変更を加えることができる。例え
ば、本発明はパラセタモールに特有の電極の如きセンサ
電極に主に関係するが、また本発明は電極と、一次また
は永久挿入手段、例えば針状プローブとの組合わせ体に
関する。また、本発明は、信号または制御装置と連結し
たまたは連結することができるかかる電極に関する。本
発明の電極は、病院の分析パラセタモールまたはパラセ
タモール誘導体感知器機に使用する改良マクロ−センサ
の製造を可能にする。Various changes can be made within the scope of the present invention. For example, the present invention relates primarily to sensor electrodes, such as the electrodes specific to paracetamol, but the present invention also relates to the combination of electrodes with primary or permanent insertion means, such as needle probes. The invention also relates to such an electrode that is or can be associated with a signal or control device. The electrodes of the present invention enable the manufacture of improved macro-sensors for use in hospital analytical paracetamol or paracetamol derivative sensing machines.
本発明の電極はマクロスケールで外科医師用として簡単
で、安価なエレクトロニックデジタル読取り器機に組込
むことができる。また分析用キットに組込まれる。The electrodes of the present invention are macroscale, simple for the surgeon, and can be incorporated into an inexpensive electronic digital reader. It will also be incorporated into an analysis kit.
マクロ−センサは、僅かに変形して指から血液サンプル
を自動的に採取し、試料をセンサと接触させ、信号を増
幅し、デジタル読取りできる装置に用いることができ
る。かかる用途においてセンサ電極はアリールアシルア
ミダーゼ、安定化剤、緩衝剤および乾燥状態の黒鉛から
構成することができる。The macro-sensor can be used in a device that can be slightly deformed to automatically take a blood sample from a finger, bring the sample into contact with the sensor, amplify the signal and digitally read it. In such applications, the sensor electrode can be composed of aryl acylamidase, stabilizer, buffer and dry graphite.
本発明は、本特許出願人の英国特許出願第8515884号明
細書「電流測定センサ電極およびその製造方法」に記載
しているスクリーン印刷電極と組合わせて用いることが
できる。The present invention can be used in combination with the screen-printed electrodes described in the applicant's British patent application No. 8515884, "Amperometric sensor electrodes and method of making the same".
第1図はすべてのボルタノメータによる測定に仕様した
標準三電極装置の略線図、 第2図は1mMの最終濃度におけるp−アミノフェノール
のサイクリック・ポルタモグラム、 第3図は1mMの濃度におけるパラセタモールのサイクリ
ック・ポルタモグラムに及ぼすアリールアシルアミダー
ゼ転化の影響を示す説明図、 第4図はpH7.0におけるパラセタモールの検量線図、 第5図はpH7.5によおけパラセタモールの検量線図、 第6図はpH8.0によおけパラセタモールの検量線図、 第7図は100%の対照血清中のpH7.0におけるパラセタモ
ールの検量線図、 第8図は本発明の分析方法と表示パラセタモール分析方
法(ケンブリッジ・ライフ・サイエンス)との分析値の
比較結果を示すグラフ、 第9図は固定化酵素電極を使用して固定されたパラセタ
モール量を検出した結果を示すグラフである。Fig. 1 is a schematic diagram of a standard three-electrode device specified for all voltammetric measurements, Fig. 2 is a cyclic portammogram of p-aminophenol at a final concentration of 1 mM, and Fig. 3 is a paracetamol at a concentration of 1 mM. Explanatory drawing showing the influence of aryl acylamidase conversion on cyclic poltamogram, Fig. 4 is a calibration curve of paracetamol at pH 7.0, Fig. 5 is a calibration curve of paracetamol at pH 7.5, Fig. 6 Is a calibration curve of paracetamol at pH 8.0, FIG. 7 is a calibration curve of paracetamol at pH 7.0 in 100% control serum, and FIG. 8 is an analysis method and a display paracetamol analysis method of the present invention (Cambridge.・ A graph showing the results of comparison of analysis values with life science, Fig. 9 shows the amount of paracetamol immobilized using immobilized enzyme electrodes. It is a graph which shows the result.
フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 G01N 27/48 311 7363−2J Continuation of front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location G01N 27/48 311 7363-2J
Claims (9)
一アミンの存在または含有量を測定するに当り、 (a) 上記試料を、作用電極および芳香族第一アミン
を与えるためN−アシル化芳香族第一アミンの加水分解
に触媒作用をすることができるアリールアシルアミダー
ゼであるEC3.5.1.13型の酵素と接触させ、 (b) 上記作用電極を、芳香族第一アミンを酸化し電
極に電荷を、メディエイタを使用せずに転送するに十分
高い電位で釣り合わせ、 (c) 試料中のN−アシル化芳香族第一アミンの存在
または含有量の指示として電流を検出または測定する ことを特徴とする液体試料の分析方法。1. A method for analyzing a liquid sample to determine the presence or content of N-acylated aromatic primary amines, comprising: (a) using the sample to provide a working electrode and an aromatic primary amine. Contacting with an enzyme of type EC3.5.1.13, which is an aryl acylamidase capable of catalyzing the hydrolysis of an acylated aromatic primary amine, (b) Balancing the charge on the oxidised electrode to transfer without the use of a mediator, (c) detecting the current as an indication of the presence or content of the N-acylated aromatic primary amine in the sample or A method for analyzing a liquid sample, which comprises measuring.
記載の分析方法。2. The analysis method according to claim 1, wherein the enzyme is obtained from bacteria.
特許請求の範囲第1または2項記載の分析方法。3. The method according to claim 1, wherein the enzyme is screen-printed on a suitable substrate.
特許請求の範囲第1〜3項のいずれか一つの項に記載の
分析方法。4. The analysis method according to claim 1, wherein the electrodes are screen-printed on a suitable substrate.
項記載の分析方法。5. The first claim in which the sample is whole blood.
Analytical method described in paragraph.
パラセタモールの誘導体の存在を測定するためのセンサ
電極において、該電極が、その表面に芳香族第1アミン
を与えるためパラセタモールまたはパラセタモールの誘
導体の加水分解に触媒作用することができるアリールア
シルアミダーゼであるEC3.5.1.13型の酵素を有し、芳香
族第一アミンを酸化し電極に電荷をメディエイタを使用
せずに転送するに十分高い電位に釣り合わせることがで
きることを特徴とするセンサ電極。6. A sensor electrode for analyzing the presence of paracetamol or a derivative of paracetamol by analyzing a liquid sample, the electrode hydrolyzing the paracetamol or derivative of paracetamol to provide an aromatic primary amine on its surface. It has an EC3.5.1.13 type enzyme, which is an aryl acylamidase that can catalyze amino acid, and oxidizes an aromatic primary amine to fish at a potential high enough to transfer charge to the electrode without the use of a mediator. A sensor electrode that can be matched.
記載のセンサ電極。7. The sensor electrode according to claim 6, wherein the enzyme is obtained from bacteria.
特許請求の範囲第6または7項記載のセンサ電極。8. The sensor electrode according to claim 6, wherein the enzyme is screen-printed on a suitable substrate.
特許請求の範囲第6〜8項のいずれか一つの項に記載の
センサ電極。9. A sensor electrode according to claim 6, wherein the electrode is screen-printed on a suitable substrate.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848425777A GB8425777D0 (en) | 1984-10-12 | 1984-10-12 | Chemical sensor |
| GB8425777 | 1984-10-12 | ||
| GB8521627 | 1985-08-30 | ||
| GB08521627A GB2168157A (en) | 1984-10-12 | 1985-08-30 | Electrochemical sensor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61274250A JPS61274250A (en) | 1986-12-04 |
| JPH0684952B2 true JPH0684952B2 (en) | 1994-10-26 |
Family
ID=26288333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60226016A Expired - Fee Related JPH0684952B2 (en) | 1984-10-12 | 1985-10-12 | Analytical method and sensor electrode |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4948727A (en) |
| EP (1) | EP0184895B1 (en) |
| JP (1) | JPH0684952B2 (en) |
| AU (1) | AU581690B2 (en) |
| CA (1) | CA1249025A (en) |
| DE (1) | DE3563064D1 (en) |
| NZ (1) | NZ213816A (en) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8618559D0 (en) * | 1986-07-30 | 1986-09-10 | Genetics Int Inc | Rhodococcus bacterium |
| GB8722278D0 (en) * | 1987-09-22 | 1987-10-28 | Genetics Int Inc | Determination of amylase |
| USRE36268E (en) * | 1988-03-15 | 1999-08-17 | Boehringer Mannheim Corporation | Method and apparatus for amperometric diagnostic analysis |
| GB8822738D0 (en) * | 1988-09-28 | 1988-11-02 | Medisense Inc | Theophylline assay |
| DE4003194A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Mannheim Gmbh | METHOD AND SENSOR ELECTRODE SYSTEM FOR THE ELECTROCHEMICAL DETERMINATION OF AN ANALYT, OR AN OXIDOR REDUCTASE, AND USE OF SUITABLE COMPOUNDS THEREFOR |
| JPH06104230B2 (en) * | 1992-06-01 | 1994-12-21 | 正和 黒田 | Biocatalyst-immobilized electrode and water treatment method using the electrode |
| US6015683A (en) * | 1992-07-15 | 2000-01-18 | Clinical Diagnostic Systems, Inc. | Dry analytical element for acetaminophen assay |
| GB9215972D0 (en) * | 1992-07-28 | 1992-09-09 | Univ Manchester | Improved analytical method |
| GB9309797D0 (en) * | 1993-05-12 | 1993-06-23 | Medisense Inc | Electrochemical sensors |
| GB9416002D0 (en) * | 1994-08-08 | 1994-09-28 | Univ Cranfield | Fluid transport device |
| US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
| US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
| US6582583B1 (en) | 1998-11-30 | 2003-06-24 | The United States Of America As Represented By The Department Of Health And Human Services | Amperometric biomimetic enzyme sensors based on modified cyclodextrin as electrocatalysts |
| US6541216B1 (en) | 1999-12-22 | 2003-04-01 | Roche Diagnostics Corporation | Amperometric biosensor test strip |
| US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
| US6576102B1 (en) | 2001-03-23 | 2003-06-10 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
| US6572745B2 (en) | 2001-03-23 | 2003-06-03 | Virotek, L.L.C. | Electrochemical sensor and method thereof |
| ES2336081T3 (en) | 2001-06-12 | 2010-04-08 | Pelikan Technologies Inc. | SELF-OPTIMIZATION PUNCTURE DEVICE WITH MEANS OF ADAPTATION TO TEMPORARY VARIATIONS IN CUTANEOUS PROPERTIES. |
| AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
| US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
| ATE497731T1 (en) | 2001-06-12 | 2011-02-15 | Pelikan Technologies Inc | DEVICE FOR INCREASING THE SUCCESS RATE OF BLOOD YIELD OBTAINED BY A FINGER PICK |
| US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
| US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| ATE485766T1 (en) | 2001-06-12 | 2010-11-15 | Pelikan Technologies Inc | ELECTRICAL ACTUATING ELEMENT FOR A LANCET |
| US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
| US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
| AU2002312521A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
| CA2448681C (en) | 2001-06-12 | 2014-09-09 | Pelikan Technologies, Inc. | Integrated blood sampling analysis system with multi-use sampling module |
| US7344894B2 (en) | 2001-10-16 | 2008-03-18 | Agilent Technologies, Inc. | Thermal regulation of fluidic samples within a diagnostic cartridge |
| US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7244265B2 (en) | 2002-04-19 | 2007-07-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US7374544B2 (en) | 2002-04-19 | 2008-05-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
| US7141058B2 (en) | 2002-04-19 | 2006-11-28 | Pelikan Technologies, Inc. | Method and apparatus for a body fluid sampling device using illumination |
| US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
| US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7582099B2 (en) | 2002-04-19 | 2009-09-01 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
| US7563232B2 (en) | 2002-04-19 | 2009-07-21 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
| US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
| US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
| US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
| US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
| US7524293B2 (en) | 2002-04-19 | 2009-04-28 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
| US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
| US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
| US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| US7485128B2 (en) | 2002-04-19 | 2009-02-03 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
| EP1501402A4 (en) | 2002-04-19 | 2008-07-02 | Pelikan Technologies Inc | DEVICE AND METHOD FOR USING A VARIABLE SPEED LANCET |
| US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
| EP1628567B1 (en) | 2003-05-30 | 2010-08-04 | Pelikan Technologies Inc. | Method and apparatus for fluid injection |
| EP1633235B1 (en) | 2003-06-06 | 2014-05-21 | Sanofi-Aventis Deutschland GmbH | Apparatus for body fluid sampling and analyte sensing |
| WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
| US7604592B2 (en) | 2003-06-13 | 2009-10-20 | Pelikan Technologies, Inc. | Method and apparatus for a point of care device |
| EP1671096A4 (en) | 2003-09-29 | 2009-09-16 | Pelikan Technologies Inc | METHOD AND APPARATUS FOR AN IMPROVED SAMPLING INTERFERENCE DEVICE |
| US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
| US20050121826A1 (en) * | 2003-12-03 | 2005-06-09 | Kiamars Hajizadeh | Multi-sensor device for motorized meter and methods thereof |
| EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
| US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
| WO2006011062A2 (en) | 2004-05-20 | 2006-02-02 | Albatros Technologies Gmbh & Co. Kg | Printable hydrogel for biosensors |
| US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
| WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
| US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
| CN100373157C (en) * | 2005-04-21 | 2008-03-05 | 复旦大学 | A microsensor for detecting liver fibrosis based on antibody-antigen method |
| WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
| US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
| US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
| US20190178832A1 (en) * | 2017-12-07 | 2019-06-13 | Pinnacle Bio, LLC | Portable microbial load detection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3506544A (en) * | 1964-10-09 | 1970-04-14 | Magna Corp | Method of determining microbial populations,enzyme activities,and substrate concentrations by electrochemical analysis |
| US4401122A (en) * | 1979-08-02 | 1983-08-30 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
| US4404066A (en) * | 1980-08-25 | 1983-09-13 | The Yellow Springs Instrument Company | Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme |
| EP0053470B1 (en) * | 1980-12-02 | 1988-01-07 | The Public Health Laboratory Service Board | Method for the estimation of n-acylated primary aromatic amines |
| EP0078636B2 (en) * | 1981-10-23 | 1997-04-02 | MediSense, Inc. | Sensor for components of a liquid mixture |
| US4528270A (en) * | 1982-11-02 | 1985-07-09 | Kabushiki Kaisya Advance Kaihatsu Kenkyujo | Electrochemical method for detection and classification of microbial cell |
| IL69644A (en) * | 1983-09-02 | 1986-11-30 | Univ Ramot | Enzyme electrodes and their preparation |
-
1985
- 1985-10-11 CA CA000492807A patent/CA1249025A/en not_active Expired
- 1985-10-11 US US06/786,974 patent/US4948727A/en not_active Expired - Lifetime
- 1985-10-11 AU AU48533/85A patent/AU581690B2/en not_active Ceased
- 1985-10-12 JP JP60226016A patent/JPH0684952B2/en not_active Expired - Fee Related
- 1985-10-14 NZ NZ213816A patent/NZ213816A/en unknown
- 1985-10-14 DE DE8585307357T patent/DE3563064D1/en not_active Expired
- 1985-10-14 EP EP85307357A patent/EP0184895B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61274250A (en) | 1986-12-04 |
| AU581690B2 (en) | 1989-03-02 |
| US4948727A (en) | 1990-08-14 |
| DE3563064D1 (en) | 1988-07-07 |
| AU4853385A (en) | 1986-04-17 |
| EP0184895A1 (en) | 1986-06-18 |
| CA1249025A (en) | 1989-01-17 |
| NZ213816A (en) | 1988-07-28 |
| EP0184895B1 (en) | 1988-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0684952B2 (en) | Analytical method and sensor electrode | |
| Han et al. | A methylene blue-mediated enzyme electrode for the determination of trace mercury (II), mercury (I), methylmercury, and mercury–glutathione complex | |
| Hilditch et al. | Disposable electrochemical biosensors | |
| Zhang et al. | Development and analytical application of an uric acid biosensor using an uricase-immobilized eggshell membrane | |
| EP0078636B2 (en) | Sensor for components of a liquid mixture | |
| Tang et al. | p-Aminophenyl phosphate: An improved substrate for electrochemical enzyme immnoassay | |
| JP3387926B2 (en) | Potentiometric biosensor and method of using the same | |
| Compagnone et al. | Glucose oxidase/hexokinase electrode for the determination of ATP | |
| Mascini et al. | Glucose electrochemical probe with extended linearity for whole blood | |
| JPS58193452A (en) | Method of measuring lactic acid or its derivative | |
| JPS63131057A (en) | Enzyme sensor | |
| JPS6026978B2 (en) | Polarographic analysis method | |
| Mascini et al. | Clinical uses of enzyme electrode probes | |
| Schubert et al. | Organic phase enzyme electrodes for the determination of hydrogen peroxide and phenol | |
| Huang et al. | Amperometric determination of total cholesterol in serum, with use of immobilized cholesterol ester hydrolase and cholesterol oxidase | |
| White et al. | Mediated amperometric biosensors | |
| Palleschi et al. | Urea determination in human sera with an ammonium ion selective electrode made with solid inner electric contact and immobilised urease | |
| Kauffmann et al. | Enzyme electrode biosensors: theory and applications | |
| Kihara et al. | Determination of creatinine with a sensor based on immobilized glutamate dehydrogenase and creatinine deiminase | |
| Messina et al. | Continuous-flow/stopped-flow system using an immunobiosensor for quantification of human serum IgG antibodies to Helicobacter pylori | |
| Kulys et al. | Urease sensors based on differential antimony electrodes | |
| RU2049991C1 (en) | Method and active member for detecting metabolites in biological fluids | |
| JP3468312B2 (en) | Method for detecting alkaline phosphatase | |
| Anik et al. | Usage of bismuth film electrode as biosensor transducer for alkaline phosphatase assay | |
| Elving | Coupling organic and biological reactions with electrochemical measurements for analytical purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |